FDA’s approval of Aimovig offers a ray of hope for migraine patients
Category: #health  By Dhananjay Punekar  Date: 2018-05-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA’s approval of Aimovig offers a ray of hope for migraine patients

In what may seem to be breakthrough in the healthcare space, the U.S. FDA has scarcely approved Aimovig, a drug developed by Novartis & Amgen to prevent migraine. Medical experts believe that the strategic move will open up a new horizon in migraine treatment, proving to be highly beneficial for chronic migraine patients who consistently suffer from the most severe kind of headache.

For the record, the newly approved medicine is basically an injection – a device that looks similar to an insulin pen and would be required to be taken on a monthly basis. It has been speculated that the drug may cost USD 6900 for a patient annually and would be made available to migraine patients within seven days.

Reportedly, migraine is a fairly common health issue across the globe, however, the ailment is so severe that it renders patients disabled and in despair. No perfect medication has been discovered so far that is capable enough to prevent migraine attacks in patients, though certain medicines are able to reduce the severity of the pain – nearly to fifty percent or even more. Sources claim that till date, medicines developed to reduce the severity of migraine are designed to treat other ailments such as hypertension. However, it was found that these drugs were less effective against migraine and could only provide temporary relief to patients in addition to rendering serious side-effects.

As per the clinical tests conducted on patients, Aimovig reported no side-effects as compared to the placebo treatment. However, the side-effects of the drug over an elongated period among the patients suffering from severe migraine pain remained to be measured.

Healthcare service providers believe that the FDA’s approval for this innovative drug will help in effectively treating nearly 2.8 million U.S. patients who suffer from extreme migraine frequency. The organization’s nod for the drug with no side-effects is likely to prove beneficial for chronic migraine patients in the near future.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...